Protagonist Therapeutics Inc (PTGX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Protagonist Therapeutics inc   (NASDAQ: PTGX)


Protagonist Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Protagonist Therapeutics Inc 's ROA in the second quarter of 2026?
Protagonist Therapeutics inc achieved a return on average assets (ROA) of 11 % in its second quarter of 2026, this is above PTGX's average return on assets of -25.53%.
Protagonist Therapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $739 million

ROA has improved compared to -16.81% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 91 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3391, from total ROA ranking in the first quarter of 2026 at 4016.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 27.12 % -6.24 % -10.32 % 16.11 % 13.5 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 81 -116 -132 46 52
Return On Assets (TTM) 11 % -16.81 % -18.72 % 6.35 % 7.45 %
PTGX's Total Ranking # 3391 # 4016 # 978 # 853 # 763
Total Assets (TTM) in million 889 697 668 702 699
Seq. Total Assets Change 27.46 % 4.38 % -4.85 % 0.42 % -5.99 %
Seq. Net Income Change 4204.76 % - - - -

PTGX's 5 Years Annual ROA >> Back to PTGX Management Effectiveness >> Compare PTGX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 38
Sector # 92
Overall # 550

Return On Assets Statistics
High Average Low
42.46 %
-25.53 %
-63.84 %
(Dec 31 2024)   (Dec 31 2016)





Financial Statements
Protagonist Therapeutics Inc 's Assets $ 889 million PTGX's Balance sheet
Protagonist Therapeutics Inc 's Income $ 163 million Quarterly PTGX's Income Statement
PTGX's Income by Division See PTGX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 0.23 % 108.26 % 44.47 % -28.78 % 7.16 %
Total Assets in million 747 745 358 248 348
Y / Y Net Income Change - - - - -
Net Income in million -130 275 -79 -127 -126
Annual Return On Assets -17.43 % 36.93 % -22.07 % -51.44 % -36.11 %

PTGX's 5 Years Annual ROA >> Back to PTGX Management Effectiveness >> Compare PTGX ROA to its Competitors



More Return On Assets Ratios
PTGX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PTGX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PTGX's Competitors
Subscribers only: Roa for Protagonist Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PTGX's Customers

You may also want to know
PTGX's Roi PTGX's Inventory Turnover Ratio PTGX's Growth Rates PTGX's Dividend Comparisons
PTGX's Profitability Ratios PTGX's Asset Turnover Ratio PTGX's Dividend Growth
PTGX's Roe PTGX's Valuation Ratios PTGX's Financial Strength Ratios PTGX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %

Date modified: 2026-09-11T09:50:26+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.